Business Wire - June 16, 1999
The founder of the company, Alfred Flores, an honor graduate of the University of Madrid as well as a graduate of the University of Colorado, has been doing research into the area of immunology for the past 15 years at his own laboratory located just outside of Lisbon, in Portugal. As a native of Spain, Mr. Flores has conducted tests on patients in Madrid which have shown complete reversal from the immune system of the HIV infection, with no reintroduction of the virus after a period of almost eighteen months.
Mr. Flores is about to do final verification of his previous results with the help and agreement of the AIDS foundation in Nassau, The Bahamas. This will involve a laboratory study of anywhere from a minimum of fifteen to thirty days, followed by the providing of the actual patients by the AIDS foundation on a ten-day study basis, at the end of which time Mr. Flores believes he will successfully be able to demonstrate, even after this short period of time, a dramatic increase in CD4+ T-Cell counts from the 200 level, normally associated with the development of AIDS itself, to normal levels of 800 - 1,200 CD4+ T cells per cubic millimeter (mm3).
Worldwide, an estimated 27.9 million people had become HIV-infected through mid-1996, and 7.7 million had developed AIDS, according to the World Health Organization (WHO). Various projections indicate that, by the year 2000, between 40 and 110 million people worldwide will be HIV-infected.
Negotiations have been under way whereby the successful completion of these tests will create the catalyst for the major financing needed for worldwide distribution of Mr. Flores' formulation, known as ``Plasma Plus,'' and immediately set up the manufacturing process for the treatment serum to back up the worldwide distribution process.
The majority stockholder in NTC is Uniprime Capital Acceptance, Inc. (OTCBB: UPCA - news) of Las Vegas, Nevada, a diversified holding company involved in the acquisition of retail automotive dealerships throughout the United States, along with planned expansion into the areas of non-prime financing, industry consulting and insurance-related services.
For further information, please contact Mr. Alfred Flores through the corporate offices of Uniprime at 1-888-892-2002 Or 1-702-798-5420. The Company intends that such statements regarding the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the ``safe harbors'' provision of the Private Securities Litigation Reform Act of 1995.
Contact: Uniprime Mr. Alfred Flores 1-888-892-2002 or 1-702-798-5420
990616
BW990608
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .